Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
31 May 2018 Photo Anja Aucamp
Microbiology department receives Research Chair in Pathogenic Yeasts Prof Carlien Pohl-Albertyn
Prof Carlien Pohl-Albertyn, Professor in the Department of Microbial, Biochemical and Food Biotechnology


The National Research Foundation (NRF) recently approved a fifth research chair for the University of the Free State (UFS), the Research Chair in Pathogenic Yeasts. Prof Carlien Pohl-Albertyn from the Department of Microbial, Biochemical and Food Biotechnology, will be chairing this research chair. 

Activities of the Research Chair in Pathogenic Yeasts builds on existing research strengths and will contribute towards understanding pathobiology of medically significant pathogenic yeasts belonging to the genera Candida and Cryptococcus. 

According to Prof Pohl-Albertyn, the research group, established in 2014, is the only one in South African focusing on understanding the role of bioactive lipids in host-pathogen interaction as well as in the search for novel drug targets. The group brought together three principal investigators, Prof Pohl-Albertyn, Prof Koos Albertyn and Dr Olihile Sebolai, with knowledge regarding various virulence factors (including immunomodulatory metabolites) produced by the Candida and Cryptococcus as well as molecular biology of yeasts. Besides the three principal investigators, the group also includes five PhD students, nine MSc students, four BSc honours students as well as two postdoctoral fellows. 

Current projects of the group include the production of immunomodulatory compounds by the yeasts, finding novel targets for antifungal drugs and the interaction between the yeasts and different hosts using a variety of infection models. In addition, the interaction between pathogenic yeasts and other co-infecting pathogens is also being investigated. 

Why research on fungal infections?
“As a result of presently used treatments for diseases and HIV/Aids, and the advances in medical interventions, many diseases no longer pose a threat to humans and life expectancy is prolonged. However, this has also caused an increase in various opportunistic infections, and most of all, fungal infections.

“With an increase in the number of individuals sensitive to invasive fungal infections, yeasts have begun to be reported more frequently as pathogens (yeasts that can cause disease). Infections by pathogenic yeasts affect a wide variety of patients. Although most of them are immunosuppressed (including HIV positive) other underlying conditions may predispose people to such infections. These include extremes of age (premature infants and the elderly), diabetes, cancer and cystic fibroses. In addition, patients hospitalised in intensive care units, as well as patients undergoing major abdominal or thoracic surgery are at high risk of invasive candidiasis. Similarly, HIV/Aids, liver cirrhosis and immunosuppressive therapy are known risk factors for invasive cryptococcosis,” said Prof Pohl-Albertyn.

According to her an important hurdle in the treatment of invasive yeast infection is the emergence of drug resistance in these pathogens. Therefore, research into pathobiology, including new drug targets, as well as novel treatment options, is a necessity. 

In line with the UFS research strategy
The NRF call for research chairs, specifically aimed at female researchers at universities that currently have fewer than 15 research chairs, came out in May 2017.

The university considers the current SARChi Chairs and the possibility of future chairs as an integral and strategic initiative to increase its national and international standing through excellent academic and research leadership. A Research Chair in Pathogenic Yeasts is therefore an invaluable addition to the UFS Research Strategy. 

The Research Chair is for five years, and is renewable for three terms.

Microbiology from University of the Free State on Vimeo.

News Archive

Wayde claims gold and silver at IAAF World Championships in London
2017-08-11

 Description: Getty Wayde Tags: Wayde van Niekerk, IAAF World Championships, Michael Johnson, Prof Francis Petersen, 200 m/400 m double 

The Olympic champion, Wayde van Niekerk, continued
his superb form over the past few months when he
won a gold medal in the 400 m and a silver in the 200 m
at the IAAF World Championships in London.
Photo: Getty Images



This is just the beginning. These were the words of an emotional Wayde van Niekerk after he completed one of the best weeks in his young career at the IAAF World Championships.

The 25-year-old Kovsie star claimed a gold medal in the 400 m in London, England, on 8 August 2017, and added a silver in the 200 m on 10 August 2017.
 
Furthermore, he was only 0.02 seconds away (in the 200 m) from achieving a 200 m/400 m double – something which was last done in 1995 at a World Championship by Michael Johnson. Van Niekerk won the 400 m in London in 43.98 s, and two days later his 20.106 s was enough for a silver in the 200 m. Ramil Guliyev from Turkey was first in 20.09 s.

Role model for Kovsie community
Once again Van Niekerk’s achievements warmed the hearts back home at the University of the Free State (UFS). “This is an extremely proud moment not only for the country, but in particular for the University of the Free State. Wayde is a role model for the entire Kovsie community, and we have been following his achievements in the international arena with great excitement. We are elated by his performances. Congratulations also to Tannie Ans and his management team,” Prof Francis Petersen, Rector and Vice-Chancellor of the UFS, said. 

So much more ahead, says star
“I really feel I worked hard for tonight and I gave it my all. And I think I have proven over and over again I deserve what I have achieved. It was a tough week for me,” Van Niekerk said in an interview with the BBC. “I am glad that I could come out again today and put on a good fight. I really believe this is just the beginning of so much more I can achieve.”

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept